Drug-Induced Liver Injury Network (DILIN) Prospective Study

AbstractBackground: Drug-induced liver injury (DILI) is an uncommon adverse drug reaction of increasing importance to the medical community, pharmaceutical industry, regulatory agencies and the general public. Objectives: The Drug-Induced Liver Injury Network (DILIN) was established to advance understanding and research into DILI by initiating a prospective registry of patients with bona fide DILI for future studies of host clinical, genetic, environmental and immunological risk factors. The DILIN was also charged with developing standardized nomenclature, terminology and causality assessment instruments. Methods: Five clinical sites, a data coordinating centre and senior scientists from the National Institute of Diabetes and Digestive and Kidney Diseases initiated the DILIN prospective study in September 2004. Eligible patients are required to meet minimal laboratory or histological criteria within 6 months of DILI onset and have other competing causes of liver injury excluded. Patients in the general community setting with pre-existing HIV, hepatitis B virus or hepatitis C virus infections and/or abnormal baseline liver biochemistries are eligible for enrolment. In addition, subjects with liver injury due to herbal products are eligible to participate. Control patients without DILI are also to be recruited in the future. Results: All referred subjects undergo an extensive review of available laboratory, pathology and imaging studies. Subjects who meet pre-defined eligibility criteria at the 6-month study visit are followed for 2 years to better define the natural history of chronic DILI. Causality assessment is determined by a panel of three hepatologists who independently assign a causality score ranging from 1 (definite) to 5 (unlikely) as well as a severity score ranging from 1 (mild) to 5 (fatal). During the first 3 years, 367 subjects were enrolled into the DILIN prospective study. Conclusion: DILIN is a multicentre research network charged with improving our understanding of the aetiologies, risk factors and outcomes of DILI in the US. The network is meeting the targeted enrolment of ten patients per month and is developing a repository of clinical data and biological samples for future studies of DILI pathogenesis and outcome.

[1]  K. Ishak,et al.  Chronic Active Hepatitis and Severe Hepatic Necrosis Associated with Nitrofurantoin , 1980, Annals of Internal Medicine.

[2]  D. Pisetsky,et al.  Methotrexate-associated hepatotoxicity: retrospective analysis of 210 patients with rheumatoid arthritis. , 1988, The American journal of medicine.

[3]  C. Bénichou.  Criteria of drug-induced liver disorders. Report of an international consensus meeting. , 1990, Journal of hepatology.

[4]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[5]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[6]  F. Ballet,et al.  Hepatotoxicity in drug development: detection, significance and solutions. , 1997, Journal of hepatology.

[7]  Carol A. Trujillo,et al.  The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. , 1998, Medical care.

[8]  C. Day,et al.  The natural history of histologically proved drug induced liver disease , 1999, Gut.

[9]  William M. Lee,et al.  Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation , 1999 .

[10]  Turbulence over arrays of obstacles in low temperature helium gas , 2000 .

[11]  M. Yuen,et al.  Safety of disease modifying anti-rheumatic agents in rheumatoid arthritis patients with chronic viral hepatitis. , 2000, Clinical and experimental rheumatology.

[12]  M W Whitehead,et al.  The causes of obvious jaundice in South West Wales: perceptions versus reality , 2001, Gut.

[13]  N. Kaplowitz.  Causality assessment versus guilt‐by‐association in drug hepatotoxicity , 2001, Hepatology.

[14]  X. Vidal,et al.  Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. , 2002, Journal of hepatology.

[15]  B. McMahon,et al.  Chronic hepatitis B , 2001, Hepatology.

[16]  Sean S. Park,et al.  Severe Hepatotoxicity Associated with the Dietary Supplement LipoKinetix , 2002, Annals of Internal Medicine.

[17]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[18]  M. Voigt,et al.  Prevalence and interaction of hepatitis B and latent tuberculosis in Vietnamese immigrants to the United States , 2002, American Journal of Gastroenterology.

[19]  B. Rumack.  Acetaminophen Hepatotoxicity: The First 35 Years , 2002, Journal of toxicology. Clinical toxicology.

[20]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[21]  J. Senior,et al.  Troglitazone-induced liver failure: a case study. , 2003, The American journal of medicine.

[22]  D. Schuppan,et al.  Hepatitis induced by Kava (Piper methysticum rhizoma). , 2003, Journal of hepatology.

[23]  M. Sulkowski,et al.  Antiretroviral-associated liver injury. , 2003, Clinics in liver disease.

[24]  Michael Seid,et al.  The PedsQL 4.0 as a pediatric population health measure: feasibility, reliability, and validity. , 2003, Ambulatory pediatrics : the official journal of the Ambulatory Pediatric Association.

[25]  J. Hoofnagle,et al.  Drug‐induced liver injury network (DILIN) , 2004, Hepatology.

[26]  M. Lambert,et al.  Current Issues in Schizophrenia: Overview of Patient Acceptability, Functioning Capacity and Quality of Life , 2004, CNS drugs.

[27]  D. Lilienfeld,et al.  The need for a population‐based surveillance system for liver disease in the United States , 2004, Pharmacoepidemiology and drug safety.

[28]  R. Andrade,et al.  HLA class II genotype influences the type of liver injury in drug‐induced idiosyncratic liver disease , 2004, Hepatology.

[29]  William M. Lee,et al.  Hepatic Findings in Long-Term Clinical Trials of Ximelagatran , 2005, Drug safety.

[30]  D. Thompson,et al.  Role of Metabolism in Drug-Induced Idiosyncratic Hepatotoxicity , 2005, Critical reviews in toxicology.

[31]  S. Gordon,et al.  The Burden of Acute Nonfulminant Drug-induced Hepatitis in a United States Tertiary Referral Center , 2005, Journal of clinical gastroenterology.

[32]  E. Björnsson,et al.  Outcome and prognostic markers in severe drug‐induced liver disease , 2005, Hepatology.

[33]  D. Wysowski,et al.  Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions. , 2005, Archives of internal medicine.

[34]  William M. Lee,et al.  Recognizing Drug-Induced Liver Injury: Current Problems, Possible Solutions , 2005, Toxicologic pathology.

[35]  Luis Rodrigo,et al.  Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.

[36]  G. Gores,et al.  Primary sclerosing cholangitis: Summary of a workshop , 2006, Hepatology.

[37]  R. Andrade,et al.  Outcome of acute idiosyncratic drug‐induced liver injury: Long‐term follow‐up in a hepatotoxicity registry , 2006, Hepatology.

[38]  Paul B Watkins,et al.  Drug‐induced liver injury: Summary of a single topic clinical research conference , 2006, Hepatology.

[39]  E. Boyko,et al.  The Prevalence and Predictors of Elevated Serum Aminotransferase Activity in the United States in 1999–2002 , 2006, The American Journal of Gastroenterology.

[40]  M. Neuman,et al.  Antiepileptic drug-induced hypersensitivity syndrome reactions. , 2006, Current drug safety.

[41]  E. Björnsson,et al.  Drug‐induced liver injury in a Swedish University hospital out‐patient hepatology clinic , 2006, Alimentary pharmacology & therapeutics.

[42]  Marina Núñez,et al.  Hepatotoxicity of antiretrovirals: incidence, mechanisms and management. , 2006, Journal of hepatology.

[43]  J. Senior,et al.  Drug-related hepatotoxicity. , 2006, The New England journal of medicine.

[44]  J. McHutchison,et al.  American Gastroenterological Association technical review on the management of hepatitis C. , 2006, Gastroenterology.

[45]  James H. Lewis,et al.  Causality assessment of drug-induced hepatotoxicity: promises and pitfalls. , 2007, Clinics in liver disease.

[46]  Peter Kraft,et al.  Drinking from the fire hose--statistical issues in genomewide association studies. , 2007, The New England journal of medicine.

[47]  Ling-xia Zhang,et al.  [AASLD practice guidelines: chronic hepatitis B]. , 2007, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology.

[48]  R. Fontana,et al.  Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug‐induced liver injury , 2008, Hepatology.

[49]  D. Harnois.  Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States , 2009 .